A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Placebo matching Test 0.9% sodium chloride solution for injectionGalvokimig
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16
Endpoint detail
Percentage of Participants with validated Investigator Global Assessment (vIGA) response at Week 16, Change from Baseline in weekly averaged Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 16, Incidence of Treatment-Emergent (TE) Adverse Events (AE), Incidence of TE Serious Adverse Events (SAEs)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.